American Chemical Society
Browse
cm9b00028_si_001.pdf (748.44 kB)
Download file

Magnetic Photoluminescent Nanoplatform Built from Large-Pore Mesoporous Silica

Download (748.44 kB)
journal contribution
posted on 2019-04-24, 00:00 authored by Fan Yang, Artiom Skripka, Maryam Sadat Tabatabaei, Sung Hwa Hong, Fuqiang Ren, Yue Huang, Jung Kwon Oh, Sylvain Martel, Xinyu Liu, Fiorenzo Vetrone, Dongling Ma
Integrating multiple components to realize cancer diagnosis and therapy in a single theranostic nanoplatform has drawn considerable attention. Herein, a multifunctional theranostic nanoplatform (mSiO2@PbS/CdS-Fe3O4) was successfully fabricated by carefully designing thiol-modified large-pore mesoporous silica nanospheres (mSiO2), followed by coordination-driven embedding of Fe3O4 nanoparticles (NPs) and PbS/CdS quantum dots (QDs) inside. The excellent feature of near-infrared (NIR) excitation and NIR emission of PbS/CdS QDs enables deep-tissue photoluminescence imaging, which was demonstrated ex vivo with tissue as thick as 14 mm. Meanwhile, owing to the presence of superparamagnetic Fe3O4 NPs, mSiO2@PbS/CdS-Fe3O4 can be rapidly confined under an external magnetic field (MF), and exhibit a significantly high T2 relaxivity in T2-weighted magnetic resonance (MR) images in vivo. When mSiO2@PbS/CdS-Fe3O4 was exposed to external physical stimuli of MF and/or NIR laser, they produced strong local heating through magnetothermal/photothermal effects. Owing to the unique mesoporous structure of mSiO2@PbS/CdS-Fe3O4, doxorubicin (DOX) was readily loaded into them and the drug-release profile was subsequently evaluated under multistimuli (pH/MF/NIR). The release of DOX was significantly enhanced at lower pH, and higher temperatures caused by magnetothermal/photothermal effects. Our results pave the road toward developing a highly powerful nanoplatform for bimodal imaging (NIR deep-tissue photoluminescence and MR imaging), and simultaneously for integrating synergistic treatment capabilities of hyperthermia and pH/MF/NIR-responsive drug release.

History